Literature DB >> 17549823

Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care.

Martin M Miner1, Louis Kuritzky.   

Abstract

Erectile dysfunction (ED) is a common, age-related disorder that diminishes quality of life for affected men and their partners. While most ED is now recognized as organic in origin, both organic and psychogenic causes often conspire to reduce sexual function in men with ED. Vasculopathy has come to be recognized as the most common cause of ED, which has elevated ED's importance in the primary care setting as a sentinel to underlying cardiovascular disease. Identification of cardiovascular risk factors should be a routine part of the evaluation for ED and is as important as taking the patient's sexual, medication, and psychosocial histories. Involving the patient's partner in evaluation and management is often valuable. Treatment with phosphodiesterase type 5 inhibitors is effective in restoring sexual function for most men with ED, but patients and their partners should be encouraged to make an informed choice from among all available treatment options.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549823     DOI: 10.3949/ccjm.74.suppl_3.s30

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  5 in total

1.  Taking the stress out of treating erectile dysfunction.

Authors:  Andries J Muller; Loren Regier; Brent Jensen
Journal:  Can Fam Physician       Date:  2010-09       Impact factor: 3.275

Review 2.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

3.  Implanted Muscle-Derived Stem Cells Ameliorate Erectile Dysfunction in a Rat Model of Type 2 Diabetes, but Their Repair Capacity Is Impaired by Their Prior Exposure to the Diabetic Milieu.

Authors:  Istvan Kovanecz; Dolores Vernet; Maryam Masouminia; Robert Gelfand; Leila Loni; James Aboagye; James Tsao; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2016-05       Impact factor: 3.802

4.  Oral and non-oral combination therapy for erectile dysfunction.

Authors:  Ajay Nehra
Journal:  Rev Urol       Date:  2007

Review 5.  A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.

Authors:  Samuel L Washington; Alan W Shindel
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.